AZD0530 in Treating Patients With Extensive Stage Small Cell Lung Cancer

Inclusion Criteria: * Histologically or cytologically confirmed small cell lung cancer * No mixed histology * Extensive stage disease, defined as any of the following: * Metastatic disease outside the chest * Contralateral supraclavicular nodes or contralateral hilar nodes that cannot be included in a single radiation port * Cytologically confirmed malignant pleural effusion * Clinically significant effusions (e.g., symptomatic pleural effusion) must be drained prior to treatment * Previously untreated disease\* OR stable disease, partial response, or complete response ≤ 4 weeks after completion of one course (four 3-week courses) of standard platinum-based chemotherapy * No symptomatic, untreated, or uncontrolled CNS metastases * CNS metastases previously treated with whole brain radiotherapy allowed * ECOG performance status (PS) 0-2 * Life expectancy ≥ 12 weeks * WBC ≥ 3,000/mm³ * ANC ≥ 1,500/mm³ * Platelet count ≥ 100,000/mm³ * Hemoglobin \> 9.0 g/dL * Total bilirubin \< 1.5 times upper limit of normal (ULN) * Alkaline phosphatase ≤ 3 times ULN * ALT and AST ≤ 3 times ULN (≤ 5 times ULN if liver involvement) * Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min * Proteinuria ≤ +1 on two consecutive dipsticks taken no less than 24hours apart * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective protection during and for up to 8 weeks after completion of study therapy * QTc interval ≤ 460 msec * No seizure di…